Letter to the Editor: In Response to Hematology...Literally and Seriously
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
Download issue as PDF
Dr. Adesina discusses the important role mentors have played in her growth and development as a medical professional specializing in SCD.
Dr. Coetzer discusses a study that provides insights into the potential of new drugs to treat CML.
Dr. Hoggatt looks at the therapeutic effects of blocking CD47 aside from alerting macrophages to devour tumor cells.
Dr. Garcia reviews a study that shows the importance of an accurate 4Ts assessment.
Dr. LaCasce discusses a new prognostic model in follicular lymphoma that incorporates both genetic and clinical factors.
Drs. Raje and Yee discuss two trials with elotuzumab and daratumumab that use monoclonal antibodies in the treatment of multiple myeloma.
Dr. Koury studies increase in platelet production and size due to the IL-1α-induced megakaryocyte rupture mechanism of rapid platelet production.
Dr. Raetz looks at a study that highlights the importance of the purine synthesis pathway in relapsed ALL.
Dr. Cuker studies the use of idarucizumab, a monoclonal antibody fragment, to reverse the anticoagulant effect of dabigatran in bleeding patients.
Dr. George discusses her diagnostic approach to lymphocytosis.
Drs. Oh and Fisher discuss the application of mass cytometry to analyze disease evolution in hematologic malignancies.
Dr. Quinn discusses the REACH study as part of several studies that look at hydroxyurea for the treatment of children with sickle cell anemia in sub-Saharan Africa.
Drs. Valent, Schumacher, Sörgel, Horny, and Groner talk about Paul Ehrlich's many achievements on the 100th anniversary of his death.
Dr. Williams talks about ASH's influence in the development of precision medicine, which is a big part of the new ASH Research Agenda.
March-April 2017Volume 14, Issue 2
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology